Quick Answer
Korro Bio, Inc. reported Total Assets of $113.51 million for the year ending 2025.
- Korro Bio, Inc. showed a decrease of -49.8% in Total Assets from 2024 to 2025.
- This data is from Korro Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $170.85 million | Q1 2020: $215.72 million | Q2 2020: $204.79 million | Q3 2020: $234.32 million | Q1 2021: $241.51 million | Q2 2021: $220.21 million | Q3 2021: $202.19 million | Q1 2022: $164.94 million | Q2 2022: $149.66 million | Q3 2022: $136.01 million | Q1 2023: $101.50 million | Q2 2023: $79.38 million | Q3 2023: $46.35 million | Q1 2024: $197.99 million | Q2 2024: $249.59 million | Q3 2024: $243.54 million | Q1 2025: $202.21 million | Q2 2025: $180.43 million | Q3 2025: $161.55 million.
- Over the full 8 years of available data (2018 to 2025), Korro Bio, Inc.'s Total Assets has grown by 154.8%.
- Historical annual values: Fiscal year 2025: $113.51 million | Fiscal year 2024: $226.24 million | Fiscal year 2023: $221.66 million | Fiscal year 2022: $73.74 million | Fiscal year 2021: $185.36 million | Fiscal year 2020: $264.72 million | Fiscal year 2019: $223.22 million | Fiscal year 2018: $44.55 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: